文献速递慢性肾脏病遗传性与小管间质肾病

NAT8基因变异、N-乙酰化氨基酸与CKD进展

NAT8 Variants, N-Acetylated Amino Acids, and Progression of CKD.
PubMed 文献 · Clin J Am Soc Nephrol · 2020-01-01

在AASK、ARIC和BioMe三个队列中分析NAT8错义变异rs13538与31种N-乙酰化氨基酸及肾衰竭的关联,发现14种氨基酸水平与rs13538相关,其中5种循环水平与肾衰竭风险独立相关;GCKD研究中尿液中这些氨基酸与肾衰竭无关。

要点

  • NAT8变异rs13538与14种N-乙酰化氨基酸水平相关。
  • 5种循环N-乙酰化氨基酸水平升高与肾衰竭风险增加相关。
  • 尿液中相应氨基酸水平与肾衰竭无显著关联。

核心结论

  • NAT8基因变异与14种N-乙酰化氨基酸相关,其中5种循环水平与肾衰竭风险独立相关。

研究设计与样本

  • 在AASK(n=962)、ARIC(n=1050)和BioMe(n=680)中分析遗传与血清代谢组数据;在GCKD(n=1624)中分析尿液代谢组数据。

主要发现

  • 31种N-乙酰化氨基酸中14种循环或尿液水平与rs13538相关(P<0.05/31)。
  • 循环N-δ-乙酰鸟氨酸、N-乙酰-1-甲基组氨酸、N-乙酰-3-甲基组氨酸、N-乙酰组氨酸和N2,N5-二乙酰鸟氨酸水平升高与肾衰竭相关,合并风险比分别为1.48(95%CI 1.21–1.81)、1.44(1.22–1.70)、1.21(1.08–1.37)、1.65(1.29–2.10)和1.41(1.17–1.71),所有P<0.05/14。
  • GCKD研究中上述N-乙酰化氨基酸的尿液水平与肾衰竭均无显著关联。

临床怎么用

  • 循环N-乙酰化氨基酸水平可能作为CKD进展风险的生物标志物,但尿液水平未显示关联。

局限性

  • 研究纳入特定人群(非裔美国人和德国CKD队列),结果外推需谨慎;尿液分析仅在GCKD中进行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Genetic variants in NAT8, a liver- and kidney-specific acetyltransferase encoding gene, have been associated with eGFR and CKD in European populations. Higher circulating levels of two NAT8-associated metabolites, N-δ-acetylornithine and N-acetyl-1-methylhistidine, have been linked to lower eGFR and higher risk of incident CKD in the Black population. We aimed to expand upon prior studies to investigate associations between rs13538, a missense variant in NAT8, N-acetylated amino acids, and kidney failure in multiple, well-characterized cohorts. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted analyses among participants with genetic and/or serum metabolomic data in the African American Study of Kidney Disease and Hypertension (AASK; n=962), the Atherosclerosis Risk in Communities (ARIC) study (n=1050), and BioMe, an electronic health record-linked biorepository (n=680). Separately, we evaluated associations between rs13538, urinary N-acetylated amino acids, and kidney failure in participants in the German CKD (GCKD) study (n=1624). RESULTS: Of 31 N-acetylated amino acids evaluated, the circulating and urinary levels of 14 were associated with rs13538 (P<0.05/31). Higher circulating levels of five of these N-acetylated amino acids, namely, N-δ-acetylornithine, N-acetyl-1-methylhistidine, N-acetyl-3-methylhistidine, N-acetylhistidine, and N2,N5-diacetylornithine, were associated with kidney failure, after adjustment for confounders and combining results in meta-analysis (combined hazard ratios per two-fold higher amino acid levels: 1.48, 1.44, 1.21, 1.65, and 1.41, respectively; 95% confidence intervals: 1.21 to 1.81, 1.22 to 1.70, 1.08 to 1.37, 1.29 to 2.10, and 1.17 to 1.71, respectively; all P values <0.05/14). None of the urinary levels of these N-acetylated amino acids were associated with kidney failure in the GCKD study. CONCLUSIONS: We demonstrate significant associations between an NAT8 gene variant and 14 N-acetylated amino acids, five of which had circulation levels that were associated with kidney failure.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Luo S, Surapaneni A, Zheng Z, et al. NAT8 Variants, N-Acetylated Amino Acids, and Progression of CKD. Clin J Am Soc Nephrol. 2020. PMID: 33380473. doi:10.2215/CJN.08600520

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。